After seemingly endless rounds of rhetoric and debate, the 2012 presidential campaign has finally reached its conclusion. We know what each of the candidates had said they would do, but now that President Obama has been re-elected, the focus has moved from politics to policy. So what can pharmaceutical manufacturers expect to happen next?
The FDA gave its blessing to Bosulif, a treatment for chronic myelogenous leukemia (CML) patients with Philadelphia chromosome-positive disease. It's a second-line approval, for patients who've failed on--or can't tolerate--another drug. Analysts figure the approval is worth $341 million in annual sales by 2016, Reuters reports.
Roche's ( $RHHBY ) new melanoma drug Zelboraf apparently works even better than researchers suspected.
More evidence that drugs and diagnostics will be playing together often: Researchers sequencing genes in colon and lung tumors found mutations that could be targeted with existing drugs. The study
No doubt about it, Roche ( $RHHBY ) is determined to dominate in personalized medicine. From the moment he took over as CEO in 2008, Severin Schwan ( photo ) has been touting targeted drugs and
Biogen Idec ( $BIIB ) has pulled off a big coup in personalized medicine. The multiple sclerosis drug Tysabri has long been weighed down by a well-known safety risk: It's linked with a potentially
Pfizer's ( $PFE ) new Xalkori cancer treatment becomes the poster child for pharma's post-mega-blockbuster strategy in a Wall Street Journal analysis of targeted treatments. Together with Roche and
As Big Pharma pursues more specialty drugs, personalized medicine is regarded as a potential boon for the industry. Giving selected patients drugs designed for their particular genetic make-up could
Bayer may have lost out in the U.K. on Nexavar, but that doesn't mean the National Institute for Health and Clinical Excellence isn't open to new cancer drugs--it's just further evidence that the
What three trends are most important to pharma these days? Generics, emerging markets and personalized medicine, according to the Harvard Business Review. Branded generics are the wave of Big